Key Highlights

  • Market data published on November 4, 2026 put Nurix Therapeutics (NASDAQ:NRIX) at USD 15.29, a decline of 40.80%, with a market Capitalization of roughly USD 1.67 billion and 5.74 million shares traded.
  • Nurix Therapeutics (NASDAQ:NRIX) collected USD 700 million upfront from Roche under their bexobrutideg collaboration and had USD 1.1 billion in cash and marketable securities.
  • For the quarter ended August 31, 2026, Revenue reached USD 673.1 million, of which USD 653.2 million was Roche license income, and Net Income came to USD 549.8 million, or USD 4.73 per diluted share.
  • Management said current cash funds operations into the second half of 2029, and the first patient has been dosed in the Phase 3 DAYBreak CLL-306 study.

Latest Company Results

The company released fiscal third quarter figures on October 12, 2026, covering the period ended August 31, 2026. Revenue was USD 673.1 million compared with USD 7.9 million a year earlier, lifted by USD 653.2 million in Roche license income. Research and Development spending was USD 79.3 million, and general and administrative costs were USD 34.4 million, including one-time deal expenses. Net income stood at USD 549.8 million versus a loss of USD 86.4 million. The Roche tie-up closed once Hart-Scott-Rodino clearance was obtained, with development costs divided 40% for Nurix and 60% for Roche, and U.S. profits and losses shared on an equal basis.

Pipeline and Losers Screen Entry

The Phase 3 DAYBreak CLL-306 study pits bexobrutideg at 600 mg once daily against pirtobrutinib in roughly 620 patients with relapsed or refractory CLL or SLL, using objective response rate and progression-free survival as co-primary endpoints. Results shown at EHA 2026 reported a median progression-free survival of 22.1 months and an objective response rate of 83.0% among heavily pretreated patients. Nurix also stopped work on NX-2127. The biggest losers screen sorts stocks by one-day decline, limited to market caps between USD 300 million and USD 2 billion. No company announcement dated November 4 turned up, so the cause of the slide remains unconfirmed.

Risk Factors and Data Checks

A 40.8% decline without any news found is out of the ordinary, so the quoted price and change, which come from screener data, should be checked before anyone relies on them. The published price to Earnings ratio of 6.61 and trailing EPS of USD 2.31 are lifted by the one-time Roche receipt and say little about the underlying business. Nurix Therapeutics (NASDAQ:NRIX) has no approved product, so its value rests on bexobrutideg trial outcomes and on partner funding. Set against USD 1.1 billion of cash as of August 31, a market cap of USD 1.67 billion implies investors were assigning about USD 0.6 billion to the pipeline, a rough calculation that mixes reporting dates. Any cash spent since August is not captured.

Where Things Stand

No confirmed cause for the 40.8% drop has surfaced, so the explanation remains open. The reported backdrop was solid: a USD 700 million upfront payment, USD 1.1 billion in cash, runway into the second half of 2029 and a Phase 3 trial underway. A move of this scale without reported news could reflect an event not yet picked up or a problem with the data. Investors in Nurix Therapeutics (NASDAQ:NRIX) should check company filings for any disclosure dated November 4 before drawing conclusions. Until a cause is pinned down, treat the move as a figure to check rather than a signal, since biotech shares can also fall on trading halts, index changes or large holder sales that never appear in a company release, and none of these has turned up here.